GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Debt-to-EBITDA

Tissue Regenix Group (LSE:TRX) Debt-to-EBITDA : 25.59 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tissue Regenix Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.51 Mil. Tissue Regenix Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £6.92 Mil. Tissue Regenix Group's annualized EBITDA for the quarter that ended in Dec. 2023 was £0.29 Mil. Tissue Regenix Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 25.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Tissue Regenix Group's Debt-to-EBITDA or its related term are showing as below:

LSE:TRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.09   Med: -0.63   Max: 21.09
Current: 21.03

During the past 13 years, the highest Debt-to-EBITDA Ratio of Tissue Regenix Group was 21.09. The lowest was -10.09. And the median was -0.63.

LSE:TRX's Debt-to-EBITDA is ranked worse than
96.77% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs LSE:TRX: 21.03

Tissue Regenix Group Debt-to-EBITDA Historical Data

The historical data trend for Tissue Regenix Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Debt-to-EBITDA Chart

Tissue Regenix Group Annual Data
Trend Jan14 Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.37 -0.63 -2.37 -10.09 21.09

Tissue Regenix Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 -6.97 -14.24 18.08 25.59

Competitive Comparison of Tissue Regenix Group's Debt-to-EBITDA

For the Biotechnology subindustry, Tissue Regenix Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tissue Regenix Group's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Debt-to-EBITDA falls into.



Tissue Regenix Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tissue Regenix Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.507 + 6.915) / 0.352
=21.09

Tissue Regenix Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.507 + 6.915) / 0.29
=25.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Tissue Regenix Group  (LSE:TRX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Tissue Regenix Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Regenix Group (LSE:TRX) Business Description

Traded in Other Exchanges
Address
Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.

Tissue Regenix Group (LSE:TRX) Headlines